A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.

A, Drilon; R, Nagasubramanian; JF, Blake; N, Ku; BB, Tuch; K, Ebata; S, Smith; V, Lauriault; GR, Kolakowski; BJ, Brandhuber; PD, Larsen; KS, Bouhana; SL, Winski; R, Hamor; WI, Wu; A, Parker; TH, Morales; FX, Sullivan; WE, DeWolf; LA, Wollenberg; PR, Gordon; DN, Douglas-Lindsay; M, Scaltriti; R, Benayed; S, Raj; B, Hanusch; AM, Schram; P, Jonsson; MF, Berger; JF, Hechtman; BS, Taylor; S, Andrews; SM, Rothenberg; DM, Hyman

doi:10.1158/2159-8290.cd-17-0507

Public

A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.

Shared by NobleBlocks on Jun 3, 2017 • 12:00 AM UTC

Authors:

Drilon A

Nagasubramanian R

Blake JF

Abstract

Larotrectinib, a selective TRK tyrosine kinase inhibitor (TKI), has demonstrated histology-agnostic efficacy in patients with TRK fusion-positive cancers. Although responses to TRK inhibition can be dramatic and durable, duration of response may eventually be limited by acquired resistance. LOXO-195...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!